<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50287">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919229</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011A2201</org_study_id>
    <secondary_id>2013-002588-24</secondary_id>
    <nct_id>NCT01919229</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients</brief_title>
  <acronym>MONALEESA-1</acronym>
  <official_title>A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products (FAMPHP)</authority>
    <authority>Spain: The Spanish Agency of Medicines and Medical Devices (AEMPS)</authority>
    <authority>Italy: Italian Medicines Agency.</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label Phase II randomized pre-surgical pharmacodynamics study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized pre-surgical pharmacodynamics study will assess the biological activity of
      LEE011 plus letrozole versus single agent letrozole in primary breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Cell cycle response rate</measure>
    <time_frame>Day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cell cycle response rate is defined by proportion of patients with natural logarithm of Ki-67 levels (expressed as percentage of baseline values) of less than 1 at the time of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the combination</measure>
    <time_frame>Up to 30 days after the last dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in expression of Retinoblastoma Protein (pRB)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (pharmacokinetics) parameters, including but not limited to, Cmax, Tmax, AUClast for LEE011 (and any relevant metabolites) and letrozole.</measure>
    <time_frame>Days 1, 8, 14 and 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG morphology</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between PK concentrations and ECG changes</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in expression of Cyclin-Dependent Kinase 1 (CDK1)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LEE011 400 mg + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 600 mg + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <arm_group_label>LEE011 400 mg + letrozole</arm_group_label>
    <arm_group_label>LEE011 600 mg + letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>LEE011 400 mg + letrozole</arm_group_label>
    <arm_group_label>LEE011 600 mg + letrozole</arm_group_label>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient is ≥ 18 years old at the time of informed consent, with newly
             diagnosed resectable breast cancer, who received no prior therapy for breast cancer

          -  Patient is postmenopausal. Postmenopausal status is defined either by:

               -  Prior bilateral oophorectomy

               -  Age ≥60

               -  Age &lt;60 and amenorrhea for 12 or more months and FSH (Follicle Stimulating
                  Hormone) and estradiol in the postmenopausal range.

          -  Patient has a histologically (and/or cytologically) confirmed diagnosis of
             estrogen-receptor positive and/or progesterone receptor positive breast cancer by
             local laboratory.

          -  Patient has a grade II or grade III invasive breast cancer

          -  Patient has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer
             defined as a negative in situ hybridization test or an Immunohistochemistry (IHC)
             status of 0, 1+ or 2+ (if IHC 2+, a negative in situ hybridization (respectively
             FISH/CISH/SISH) test is required) by local laboratory testing

          -  Patient has at least one breast lesion with a diameter of ≥1.0 cm by the most
             accurate imaging modality used.

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Patient has received any prior therapy for breast cancer.

          -  Patient has a concurrent malignancy or malignancy within 3 years of randomization,
             with the exception of adequately treated, basal cell skin cancer or squamous cell
             carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.

          -  Patient has active cardiac disease or a history of cardiac dysfunction including any
             of the following:

               -  History of angina pectoris, symptomatic pericarditis, or myocardial infarction
                  within 12 months prior to study entry

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Documented cardiomyopathy

               -  Patient has a Left Ventricular Ejection Fraction (LVEF) &lt; 50% as determined by
                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)

               -  History of ventricular, supraventricular, nodal arrhythmias, or any other
                  cardiac arrhythmias, Long QT Syndrome or conduction abnormality in the previous
                  12 months.

               -  Family history of QTc prolongation or of unexplainable sudden death at &lt;50 years
                  of age.

               -  On screening 12 lead ECG, any of the following cardiac parameters: bradycardia
                  (heart rate &lt; 50 at rest), tachycardia (heart rate &gt; 90 at rest), PR interval &gt;
                  220 msec, QRS interval &gt;109 msec, or QTcF &gt;450 msec.

               -  Systolic blood pressure &gt;160 mmHg or &lt;90 mmHg.

          -  Patient is currently receiving any of the following medications (see

        Appendix 1 for details):

          -  That are known strong inducers or inhibitors of CYP3A4.

          -  That have a narrow therapeutic window and are predominantly metabolized through
             CYP3A4.

          -  That have a known risk to prolong the QT interval or induce Torsades de Pointes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham SC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Quinn</last_name>
      <phone>205-934-3866</phone>
      <email>rquinn@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group SC</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly M. Kinser</last_name>
      <phone>+1 479 872 8130</phone>
      <email>hkinser@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Thaddeus Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly M. Kelly</last_name>
      <phone>+1 310 582 6324</phone>
      <email>kmkelly@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Alsterlind Hurvitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center at Chicago SC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Collier</last_name>
      <phone>312-355-5112</phone>
      <email>collierj@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Kent Hoskins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital SC-9</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Hepp</last_name>
      <phone>617-724-0878</phone>
      <email>rhepp@partners.org</email>
    </contact>
    <investigator>
      <last_name>Aditya Bardia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic SC-4</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Lange</last_name>
      <phone>901-683-0055</phone>
      <email>alange@acornresearch.net</email>
    </contact>
    <investigator>
      <last_name>Lee S. Schwartzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advantage Clinical Research SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristie Appleton</last_name>
      <email>kristie@nashvillebreastcenter.com</email>
    </contact>
    <investigator>
      <last_name>Pat Whitworth Jr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Herrick</last_name>
      <phone>713-794-1014</phone>
      <email>amherrick@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Funda Meric-Bernstam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-positive</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>LEE011</keyword>
  <keyword>Letrozole</keyword>
  <keyword>CDK</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pre-surgical</keyword>
  <keyword>Postmenopausal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
